secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2023-01-18T23:59:59+00:00
Accession:  0001493152-23-001787
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx PK substudy shows >50% reduction in systemic drug exposure with RenovoTAMP
--------------------------------------------------------------------------------

- In 13 LAPC patients, intra-arterial gemcitabine via RenovoTAMP reduced systemic drug exposure by >50% vs IV.
- Data presented at ASCO GI Symposium January 19-21, 2023, along with three additional abstracts.
- TIGeR-PaC trial: 47 of 114 target patients randomized; 25 deaths reported to date.
- Additional abstracts cover mesenteric venous thrombosis prevalence and SBRT vs IMRT tolerability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223001787/0001493152-23-001787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223001787/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-001787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer